Browse by Author "Pérez Encinas, Manuel Mateo"

A good adherence to ELN 09 recommendations in chronic myeloid leukemia (CML) treatment with imatinib, is associated with better outcomes in patients treated outside clinical trials

2012- Pérez Encinas, Manuel Mateo

A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-IDA or flago-IDA

2014- Pérez Encinas, Manuel Mateo

ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY

2014- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

2019- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Alonso Vence, Natalia; Díaz Arias, José; Díaz Varela, Nicolás; [et al.]

Azacitidine as front-line therapy in AML: Results from spanish national registry. Alma study investigators

2012- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction

2015- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score

2015- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

2011- Pérez Encinas, Manuel Mateo

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

2014- Pérez Encinas, Manuel Mateo

DO CHRONIC MYELOID LEUKEMIA PATIENTS WITH LATE "WARNING" RESPONSES BENEFIT FROM SWITCHING THERAPY TO A SECOND GENERATION TYROSINE KINASE INHIBITOR?

2014- Pérez Encinas, Manuel Mateo

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling

2020- MOSQUERA ORGUEIRA, ADRIAN; Díaz Arias, José; Cid López, Miguel; Peleteiro Raindo, Andrés; Antelo Rodríguez, Beatriz; [et al.]

Intensive (2+5) or semi-intensive (FLUGA) chemotherapy for patients with acute myeloid leukemia who are 70 years of age or older

2013- Pérez Encinas, Manuel Mateo

LIF, a novel STAT5-regulated gene, is aberrantly expressed in myeloproliferative neoplasms.

2011- Pérez Encinas, Manuel Mateo; Quinteiro García, Celsa

MANAGEMENT OF RENAL IMPAIRMENT IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: PRELIMINARY DATA OF A LARGE OBSERVATIONAL, PROSPECTIVE STUDY

2014- Pérez Encinas, Manuel Mateo

Oral anticoagulant therapy for the prevention of recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia

2015- Pérez Encinas, Manuel Mateo

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

2015- Pérez Encinas, Manuel Mateo

Outcomes of chronic myeloid leukemia (CML) patients who stopped second generation tyrosine kinase inhibitors (2GTKIS) as second line treatment. results of the CML Spanish National Registry (RELMC)

2012- Pérez Encinas, Manuel Mateo

Renal Response in Patients (Pts) With Relapsed Refractory Multiple Myeloma (RRMM) and severe renal impairment (RI): Interim data from a large observational, prospective study

2015- Pérez Encinas, Manuel Mateo

Renal response in patients (PTS) with relapsed refractory multiple myeloma (RRMM): Interim data of a large observational, prospective study

2014- Pérez Encinas, Manuel Mateo

Retrospective study of azacitidine in patients of advanced age with acute myeloid leukemia (lma). Results of the alma/ pethema cohort in comparison with the mrc risk index score

2015- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

RUNA digital repository

Browse by Author "Pérez Encinas, Manuel Mateo"

A good adherence to ELN 09 recommendations in chronic myeloid leukemia (CML) treatment with imatinib, is associated with better outcomes in patients treated outside clinical trials ﻿

A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-IDA or flago-IDA ﻿

ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY ﻿

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution ﻿

Azacitidine as front-line therapy in AML: Results from spanish national registry. Alma study investigators ﻿

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction ﻿

Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score ﻿

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. ﻿

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor? ﻿

DO CHRONIC MYELOID LEUKEMIA PATIENTS WITH LATE "WARNING" RESPONSES BENEFIT FROM SWITCHING THERAPY TO A SECOND GENERATION TYROSINE KINASE INHIBITOR? ﻿

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling ﻿

Intensive (2+5) or semi-intensive (FLUGA) chemotherapy for patients with acute myeloid leukemia who are 70 years of age or older ﻿

LIF, a novel STAT5-regulated gene, is aberrantly expressed in myeloproliferative neoplasms. ﻿

MANAGEMENT OF RENAL IMPAIRMENT IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: PRELIMINARY DATA OF A LARGE OBSERVATIONAL, PROSPECTIVE STUDY ﻿

Oral anticoagulant therapy for the prevention of recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia ﻿

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia ﻿

Outcomes of chronic myeloid leukemia (CML) patients who stopped second generation tyrosine kinase inhibitors (2GTKIS) as second line treatment. results of the CML Spanish National Registry (RELMC) ﻿

Renal Response in Patients (Pts) With Relapsed Refractory Multiple Myeloma (RRMM) and severe renal impairment (RI): Interim data from a large observational, prospective study ﻿

Renal response in patients (PTS) with relapsed refractory multiple myeloma (RRMM): Interim data of a large observational, prospective study ﻿

Retrospective study of azacitidine in patients of advanced age with acute myeloid leukemia (lma). Results of the alma/ pethema cohort in comparison with the mrc risk index score ﻿

A good adherence to ELN 09 recommendations in chronic myeloid leukemia (CML) treatment with imatinib, is associated with better outcomes in patients treated outside clinical trials

A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-IDA or flago-IDA

ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

Azacitidine as front-line therapy in AML: Results from spanish national registry. Alma study investigators

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction

Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

DO CHRONIC MYELOID LEUKEMIA PATIENTS WITH LATE "WARNING" RESPONSES BENEFIT FROM SWITCHING THERAPY TO A SECOND GENERATION TYROSINE KINASE INHIBITOR?

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling

Intensive (2+5) or semi-intensive (FLUGA) chemotherapy for patients with acute myeloid leukemia who are 70 years of age or older

LIF, a novel STAT5-regulated gene, is aberrantly expressed in myeloproliferative neoplasms.

MANAGEMENT OF RENAL IMPAIRMENT IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: PRELIMINARY DATA OF A LARGE OBSERVATIONAL, PROSPECTIVE STUDY

Oral anticoagulant therapy for the prevention of recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

Outcomes of chronic myeloid leukemia (CML) patients who stopped second generation tyrosine kinase inhibitors (2GTKIS) as second line treatment. results of the CML Spanish National Registry (RELMC)

Renal Response in Patients (Pts) With Relapsed Refractory Multiple Myeloma (RRMM) and severe renal impairment (RI): Interim data from a large observational, prospective study

Renal response in patients (PTS) with relapsed refractory multiple myeloma (RRMM): Interim data of a large observational, prospective study

Retrospective study of azacitidine in patients of advanced age with acute myeloid leukemia (lma). Results of the alma/ pethema cohort in comparison with the mrc risk index score